Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;39(8):1461-1470.
doi: 10.1007/s10096-020-03861-4. Epub 2020 Mar 14.

The predictive value of CXCL13 in suspected Lyme neuroborreliosis: a retrospective cross-sectional study

Fredrikke Christie Knudtzen  1   2 , Anna Christine Nilsson  3 , Joppe W Hovius  4 , Sigurdur Skarphedinsson  5   6
Affiliations

The predictive value of CXCL13 in suspected Lyme neuroborreliosis: a retrospective cross-sectional study

Fredrikke Christie Knudtzen et al. Eur J Clin Microbiol Infect Dis. 2020 Aug.

Abstract

The role of CXCL13 as a marker of Lyme neuroborreliosis (LNB) is under investigation, and CXCL13 is not part of routine diagnostics in suspicion of LNB. Our aim was to find the optimal cut-off value of CXCL13 for LNB in a Danish population and to investigate the role of CXCL13 both in early LNB and as a discriminatory marker between LNB and other neuroinflammatory disorders. We conducted a retrospective cross-sectional study including all patients with a cerebrospinal CXCL13 test performed at the Department of Clinical Immunology, Odense University Hospital, Denmark, between 1 January 2015 and 31 December 2018. We included 619 patients, of which 51 had definite LNB, 14 patients had possible LNB with neurological symptoms suggestive of LNB and pleocytosis but no intrathecal Borrelia antibodies, eight patients had prior LNB and 546 had no LNB. With an optimal CXCL13 cut-off of 49 ng/L we found a sensitivity of 100% and specificity of 94% (AUC 0.988, 95% CI 0.980-0.996) when patients treated with antibiotics prior to lumbar puncture were excluded (n = 130). All patients with possible LNB had a CXCL13 value above the cut-off value; 18/546 patients (3.3%) without LNB had a CXCL13 value ≥ 50 ng/L. While CXCL13 cannot be used as a stand-alone test, it can be used as a reliable additional marker in treatment-naive patients suspected of LNB. CXCL13 can be used to monitor treatment response in LNB patients.

Keywords: CXCL13; Cerebrospinal fluid; Lyme neuroborreliosis; Predictive marker.

PubMed Disclaimer

References

    1. Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I, European Federation of Neurological S (2010) EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 17(1):8–16, e11-14. https://doi.org/10.1111/j.1468-1331.2009.02862.x - DOI - PubMed
    1. Stanek G, Wormser GP, Gray J, Strle F (2012) Lyme borreliosis. Lancet 379(9814):461–473. https://doi.org/10.1016/s0140-6736(11)60103-7 - DOI - PubMed
    1. Halperin JJ (2011) Neurologic manifestations of Lyme disease. Curr Infect Dis Rep 13(4):360–366. https://doi.org/10.1007/s11908-011-0184-x - DOI - PubMed
    1. Djukic M, Schmidt-Samoa C, Lange P, Spreer A, Neubieser K, Eiffert H, Nau R, Schmidt H (2012) Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. J Neurol 259(4):630–636. https://doi.org/10.1007/s00415-011-6221-8 - DOI - PubMed
    1. Borde JP, Meier S, Fingerle V, Klier C, Hubner J, Kern WV (2012) CXCL13 may improve diagnosis in early neuroborreliosis with atypical laboratory findings. BMC Infect Dis 12:344. https://doi.org/10.1186/1471-2334-12-344 - DOI - PubMed - PMC

Publication types

LinkOut - more resources